These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35080920)

  • 1. Special Focus Issue - Targeted protein degradation: a new paradigm in medicinal chemistry.
    Wall H
    Future Med Chem; 2022 Jan; 14(3):115-117. PubMed ID: 35080920
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteolysis-targeting chimeras: a kaleidoscope of targeted protein degradation.
    Mou Y; Wen S; Gao X; Jiang ZY
    Future Med Chem; 2022 Jan; 14(3):139-141. PubMed ID: 34814705
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Present and Future of Novel Protein Degradation Technology.
    Xia L; Liu W; Song Y; Zhu H; Duan Y
    Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.
    Jevtić P; Haakonsen DL; Rapé M
    Cell Chem Biol; 2021 Jul; 28(7):1000-1013. PubMed ID: 33891901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of ubiquitin ligases in the PROTAC drug design.
    Chen Y; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Selective Target Degradation by Folate-Caged PROTACs.
    Liu J; Chen H; Liu Y; Shen Y; Meng F; Kaniskan HÜ; Jin J; Wei W
    J Am Chem Soc; 2021 May; 143(19):7380-7387. PubMed ID: 33970635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted protein degradation: expanding the toolbox.
    Schapira M; Calabrese MF; Bullock AN; Crews CM
    Nat Rev Drug Discov; 2019 Dec; 18(12):949-963. PubMed ID: 31666732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches.
    Scholes NS; Mayor-Ruiz C; Winter GE
    Cell Chem Biol; 2021 Jul; 28(7):1048-1060. PubMed ID: 33811812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
    Blaquiere N; Villemure E; Staben ST
    J Med Chem; 2020 Aug; 63(15):7957-7985. PubMed ID: 32142281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands.
    Han B
    J Biol Chem; 2020 Nov; 295(45):15280-15291. PubMed ID: 32859748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.
    Burslem GM; Smith BE; Lai AC; Jaime-Figueroa S; McQuaid DC; Bondeson DP; Toure M; Dong H; Qian Y; Wang J; Crew AP; Hines J; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):67-77.e3. PubMed ID: 29129716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory.
    Poongavanam V; Kihlberg J
    Future Med Chem; 2022 Jan; 14(3):123-126. PubMed ID: 34583518
    [No Abstract]   [Full Text] [Related]  

  • 16. Towards the Targeted Protein Degradation of PRMT1.
    Martin PL; Pérez-Areales FJ; Rao SV; Walsh SJ; Carroll JS; Spring DR
    ChemMedChem; 2024 Aug; 19(16):e202400269. PubMed ID: 38724444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
    Kannt A; Đikić I
    Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.
    Galdeano C
    Future Med Chem; 2017 Mar; 9(4):347-350. PubMed ID: 28263082
    [No Abstract]   [Full Text] [Related]  

  • 20. PROTAC-mediated crosstalk between E3 ligases.
    Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
    Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.